Abstract

UPDATE OF THE NEUROPROTECTIVE EFFECT OF MAO-B INHIBITORS THERAPY ON PARKINSON’S DISEASE

Rizta Widya Pangestika* and Suharjono

Abstract

Parkinson’s disease was marked by stiffness, bradykinesia, resting tremor, and postural instability occurring due to various causes that were mainly idiopathic causes. Monoamine oxidase B inhibitor, also known as MAO-B inhibitor was crucial for therapy against Parkinson’s disease. The inhibitor metabolized dopamine selectively, blocking one of the enzymes that broke dopamine in brains and enhancing the effects. In Parkinson’s disease, Selegiline was the first generation of MAO-B inhibitors used for therapies; whereas Rasagiline was the second generation of the same inhibitor. The review emphasized the pharmacological aspect, side effect, and neuroprotective effect of Selegiline and Rasagiline on Parkinson’s disease.

Keywords: Parkinson’s disease, neuroprotective effect, MAO-B inhibitors, Selegiline, Rasagiline.